217
Participants
Start Date
January 11, 2021
Primary Completion Date
November 1, 2023
Study Completion Date
April 30, 2026
tucatinib
300 mg orally twice daily
trastuzumab
Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1
fulvestrant
Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.
Cliniques Universitaires Saint-Luc, Brussels
Universitair Ziekenhuis Antwerpen, Edegem
AZ Sint-Maarten, Mechelen
CHU de Liege, Liège
AZ Groeninge, Kortrijk
Institut Catala d'Oncologia Hospitalet, L'Hospitalet de Llobregat
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
NYU Langone Medical Center, New York
Icahn School of Medicine at Mount Sinai, New York
Perlmutter Cancer Center at NYU Langone GYN Oncology Associates, Mineola
Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
Charite Universitatsmedizin Berlin, Berlin
Charite Universitatsmedizin Berlin, Berlin
Seoul National University Bundang Hospital, Seongnam-si
UPMC Hillman Cancer Center - Washington, Washington
Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative lstituto Europeo di Oncologia, Milan
Virginia Cancer Specialists, PC, Gainesville
Virginia Cancer Specialists, PC, Fairfax
Virginia Cancer Specialists, PC, Arlington
Virginia Cancer Specialists, PC, Alexandria
Duke University Medical Center/Duke Cancer Center, Durham
Prisma Health Cancer Institute, Boiling Springs
Prisma Health Cancer Institute, Greenville
Prisma Health Cancer Institute, Greenville
Prisma Health Cancer Institute, Easley
Prisma Health Cancer Institute, Greer
Prisma Health Cancer Institute, Seneca
Moffitt Cancer Center, Tampa
Tennessee Oncology, PLLC, Gallatin
Tennessee Oncology, PLLC, Hendersonville
Tennessee Oncology, PLLC, Shelbyville
Tennessee Oncology, PLLC, Nashville
OSU Wexner Medical Center, Gynecologic Oncology at Mill Run, Hilliard
OSU Wexner Medical Center, Outpatient Care Lewis Center, Lewis Center
OSU Wexner Medical Center, Outpatient Care New Albany, Westerville
OSU Wexner Medical Center, CarePoint East, Columbus
OSU Wexner Medical Center, Ohio State University Hospital East, Columbus
OSU Wexner Medical Center, Arther G. James Cancer Hospital, and Solove Research Institute, Columbus
OSU Wexner Medical Center, Investigational Drug Services(IP Ship to), Columbus
Osu Wexner Medical Center, The Ohio State University Hospital, Columbus
OSU Wexner Medical Center, Stefanie Spieman Comprehensive Breast Center, Columbus
OSU Wexner Medical Center, Martha Morehouse Medical Plaza, Columbus
OSU Wexner Medical Center, OutPatient Care Upper Arlington, Columbus
OSU Wexner Medical Center, CarePoint Gahanna, Gahanna
University Hospitals Cleveland Medical Center, Cleveland
UH Minoff Health Center at Chagrin Highlands, Orange
Hospital Clínico Universitario de Valencia. Fundación Investigación Clínico de Valencia., Valencia
Ascires Eresa Campanar, Valencia
Hospital Vithas Valencia 9 de Octubre, Valencia
1 S Park St Medical Center, Madison
University of Wisconsin Clinical Science Center, Madison
Metro Minnesota Community Oncology Research Consortium (MMCORC), Saint Louis Park
Minnesota Oncology Hematology, PA, Coon Rapids
Washington University School of Medicine - Obstetrics & Gynecology [Academic Offices), St Louis
Barnes-Jewish Hospital Investigational Drug Pharmacy (IDS), St Louis
Washington University School of Medicine - Obstetrics & Gynecology, St Louis
Washington University School of Medicine [Patient Clinics], St Louis
Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
US Oncology Investigational Product Center (IPC), Irving
US Oncology Investigational Products Center (IPC), Irving
US Oncology lnvestigational Products Center (IPC), Irving
Texas Oncology - Central South, Waco
Texas oncology-West Texas, Abilene
Rocky Mountain Cancer Centers, Aurora
Rocky Mountain Cancer Centers, Thornton
Rocky Mountain Cancer Centers, Boulder
Huntsman Cancer Institute, University of Utah, Salt Lake City
HonorHealth, Phoenix
HonorHealth, Tempe
The University of Arizona Cancer Center-North Campus, Tucson
City of Hope Torrance, Torrance
City of Hope at Long Beach Worsham, Long Beach
City of Hope at Long Beach Elm, Long Beach
Koman Family Outpatient Pavilion, La Jolla
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion), La Jolla
UC San Diego Moores Cancer Center- Investigational Drug Services, La Jolla
UC San Diego Moores Cancer Center, La Jolla
City of Hope at Irvine Sand Canyon, Irvine
City of Hope at Huntington Beach, Huntington Beach
City of Hope at Newport Beach Lido, Newport Beach
Northwest Cancer Specialists, P.C., Portland
Northwest Cancer Specialists, P.C., Tigard
Northwest Cancer Specialists, P.C., Portland
Fred Hutchinson Cancer Center, Seattle
University of Washington Medical Center, Seattle
Northwest Cancer Specialists, P.C., Vancouver
Grand Hopital de Charleroi, Charleroi
Aichi Cancer Center Hospital, Nagoya
National Cancer Center Hospital East, Kashiwa-shi
St. Marianna University School of Medicine Hospital, Kawasaki
Kindai University Hospital, Osakasayama-shi
National Cancer Center Hospital, Cho-ku
The Cancer Institute Hospital of JFCR, Tokyo
Severance Hospital Yonsei University Health System, Seoul
Seoul National University Hospital, Seoul
Samsung Medical Center, Seoul
Cetir Centre Medic, Barcelona
Sarah Cannon Research Institute UK, London
Diagnostic Centre, London
The Royal Marsden NHS Foundation Trust, Sutton
Guy's Hospital, London
Jonathan Poon, London
The Royal Marsden NHS Foundation Trust, London
The Harley Street Clinic, London
Radiology, London
Seagen, a wholly owned subsidiary of Pfizer
INDUSTRY